Bryn Mawr Capital Management LLC Sells 245 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bryn Mawr Capital Management LLC lowered its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 69,370 shares of the medical equipment provider’s stock after selling 245 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Zimmer Biomet were worth $8,442,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Naples Money Management LLC bought a new stake in Zimmer Biomet during the 4th quarter worth approximately $35,000. Activest Wealth Management increased its holdings in Zimmer Biomet by 410.4% during the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 275 shares during the period. Peoples Bank KS bought a new stake in Zimmer Biomet during the 3rd quarter worth approximately $48,000. Impact Partnership Wealth LLC bought a new stake in Zimmer Biomet during the 3rd quarter worth approximately $52,000. Finally, Blue Trust Inc. increased its holdings in Zimmer Biomet by 48.4% during the 4th quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock worth $52,000 after acquiring an additional 153 shares during the period. Institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. StockNews.com lowered shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a report on Monday, February 19th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $130.00 target price on shares of Zimmer Biomet in a report on Friday, February 23rd. Citigroup increased their price target on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. Royal Bank of Canada reissued an “outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 9th. Finally, Barclays increased their price target on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a report on Monday, February 12th. One analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $139.39.

Insider Transactions at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the transaction, the vice president now owns 44,145 shares in the company, valued at $5,677,929.90. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.95% of the company’s stock.

Zimmer Biomet Trading Down 0.3 %

NYSE:ZBH opened at $119.35 on Friday. The company has a 50-day moving average price of $125.98 and a 200-day moving average price of $119.52. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $149.25. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39. The stock has a market cap of $24.52 billion, a price-to-earnings ratio of 24.41, a P/E/G ratio of 2.20 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.15 by $0.05. The company had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. Zimmer Biomet’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the business earned $1.88 EPS. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.80%. Zimmer Biomet’s dividend payout ratio is currently 19.63%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.